Hebei Meiosai Biotechnology

Hebei Meiou Saiaojin Biotechnology is a Chinese biopharmaceutical company specializing in the development of advanced cell therapies, with a primary focus on "off-the-shelf" natural killer (NK) cell products. The company's lead program, ZMPB-NK006, is an allogeneic NK cell therapy derived from healthy donor peripheral blood or umbilical cord blood, designed to treat advanced or metastatic solid tumors. Unlike traditional autologous therapies, Meiosai's platform enables large-scale manufacturing and immediate clinical use without the need for patient-specific matching. The company is part of the Sino-US Saiaojin Group and collaborates with Saiaosibo Biotechnology for research and regulatory filings. Its pipeline aims to address the high unmet need in solid tumor oncology through cost-effective and accessible immunotherapy solutions.